Suzawa H, Kikuchi S, Ichikawa K, Arai N, Tazawa S, Tsuchiya O, Momose Y, Shibata N, Sugimoto C, Hamano S
Medical Information, Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan.
Nihon Yakurigaku Zasshi. 1992 Apr;99(4):231-9. doi: 10.1254/fpj.99.231.
We studied the inhibitory effects of tranilast, an anti-allergic drug, on the human keloid tissues implanted into the dorsal skin of athymic nude mice and on the growth of keloid fibroblast in vitro. In the keloid tissue-implanted model, tranilast (50-200 mg/kg, p.o.) decreased the weight of the keloid tissue as triamcinolone (25 mg/kg, p.o.) did. Tranilast (200 mg/kg, p.o.) reduced the hydroxyproline content of implanted tissues. Tranilast (3-300 microM) also inhibited the collagen synthesis by keloid fibroblast in vitro. Only a high concentration of tranilast (300 microM) suppressed the glycosaminoglycan synthesis and cell proliferation of keloid fibroblasts. Moreover, tranilast scarcely affected the fibronectin production. Triamcinolone (10 microM) also inhibited glycosaminoglycan synthesis and cell proliferation. These results suggest that the inhibitory effect of tranilast on the keloid tissues is related to its inhibition of the collagen synthesis of fibroblasts. Tranilast would be useful as a therapeutic drug for the treatment of keloids.
我们研究了抗组胺药曲尼司特对植入无胸腺裸鼠背部皮肤的人瘢痕疙瘩组织以及对瘢痕疙瘩成纤维细胞体外生长的抑制作用。在植入瘢痕疙瘩组织的模型中，曲尼司特（50 - 200毫克/千克，口服）与曲安奈德（25毫克/千克，口服）一样，可减轻瘢痕疙瘩组织的重量。曲尼司特（200毫克/千克，口服）可降低植入组织的羟脯氨酸含量。曲尼司特（3 - 300微摩尔）在体外也能抑制瘢痕疙瘩成纤维细胞的胶原蛋白合成。只有高浓度的曲尼司特（300微摩尔）可抑制瘢痕疙瘩成纤维细胞的糖胺聚糖合成和细胞增殖。此外，曲尼司特几乎不影响纤连蛋白的产生。曲安奈德（10微摩尔）也能抑制糖胺聚糖合成和细胞增殖。这些结果表明，曲尼司特对瘢痕疙瘩组织的抑制作用与其对成纤维细胞胶原蛋白合成的抑制有关。曲尼司特有望成为治疗瘢痕疙瘩的有效药物。
